Background: Tuberculosis disproportionately affects disadvantaged populations. Individuals with comorbidities such as HIV and diabetes are more vulnerable to developing TB. Tshopo Province presents disparities in health outcomes across different health zones, indicating challenges in care management. The objective of this study was to describe the clinical, diagnostic, and evolutionary profiles of TB patients followed up at Kisangani’s Tuberculosis Diagnostic and Treatment Centers. Materials and Methods: This was a retrospective descriptive study conducted from January 2020 to June 2023 involving 1204 TB patients followed up in the TB diagnostic centers of Kisangani. The data were collected via Kobotoolbox, processed in Excel, and analysed via Stata. Results: The study population consisted primarily of young adult males, with a predominance of pulmonary tuberculosis (62.79%) and classic TB symptoms (cough, fever, night sweats). Despite a high treatment success rate (95.51%), TB remains a major cause of mortality among treatment failure patients, particularly in the presence of HIV coinfection. Conclusion: Tuberculosis remains a major public health problem in Kisangani, primarily affecting young adults. Despite encouraging treatment success rates, TB-related mortality rates remain high, highlighting the need to strengthen prevention, screening, and integrated HIV-TB care strategies.
References
[1]
Diabaté, S., Baya, B., Sanogo, M., Diarra, B., Toloba, Y., Berthé, G., et al. (2016) Epidémiologie et recherche sur la tuberculose au Mali: Etat des lieux. Revue Malienne d’Infectiologie et de Microbiologie, 6, 2-6. https://doi.org/10.53597/remim.v6i0.831
[2]
Traoré, F.A., Sako, F.B., Sylla, D., Bangoura, M., Kpamy, D.O., Traoré, M., et al. (2014) Épidémiologie de la tuberculose pulmonaire bacillifère selon le statut VIH des patients suivis dans le service des maladies infectieuses de Conakry (Guinée). Bulletin de la Société de pathologie exotique, 107, 346-349. https://doi.org/10.1007/s13149-014-0396-z
[3]
World Health Organization (2015) The End TB Strategy. WHO/HTM/TB/2015.19.
[4]
El Kamel, A., Joobeur, S., Skhiri, N., Cheikh Mhamed, S., Mribah, H. and Rouatbi, N. (2015) La lutte antituberculeuse dans le monde. Revue de Pneumologie Clinique, 71, 181-187. https://doi.org/10.1016/j.pneumo.2014.03.004
[5]
Chakaya, J., Khan, M., Ntoumi, F., Aklillu, E., Fatima, R., Mwaba, P., et al. (2021) Global Tuberculosis Report 2020—Reflections on the Global TB Burden, Treatment and Prevention Efforts. International Journal of Infectious Diseases, 113, S7-S12. https://doi.org/10.1016/j.ijid.2021.02.107
[6]
Chauffour, J., Diah, T., Kaswa, M., Herrera, E. and Diah, T. (2024) Enquête sur la qualité des services de tuberculose en République démocratique du Congo. https://www.tbdiah.org/wp-content/uploads/2024/02/DRC-QTSA-Report_French-TR-23-507-TB_508c.pdf
[7]
USAID (2015) Guide de Prise en Charge de la Tuberculose PATI-5–TB DIAH. https://www.tbdiah.org/resources/publications/guide-de-prise-en-charge-de-la-tuberculose-pati-5/
[8]
Collins, B.A. (2022) Qu’est ce qui entrave la lutte contre la Tuberculose en Afrique? WHO. https://www.afro.who.int/fr/news/quest-ce-qui-entrave-la-lutte-contre-la-tuberculose-en-afrique
[9]
Bisuta, S.F., Kayembe, P.K., Kabedi, M.B., Situakibanza, H.N., Ditekemena, J.D., Bakebe, A.M., et al. (2018) Tendances de la tuberculose pulmonaire bactériologiquement confirmée et issues thérapeutiques en République Démocratique du Congo: 2007-2017. Annals of African Medicine, 11, 2974-2984.
[10]
The World Bank (2022) World Bank. Rapport sur la lutte contre la tuberculose dans le monde. https://www.worldbank.org/en/search
[11]
Musafiri, J., Mbayo, P.M., Bakaswa, G., Kaswa, M. and Losimba Likwela, J. (2013) Séroprévalence du VIH chez les tuberculeux à Kisangani en République Démocratique du Congo. Santé Publique, 25, 483-490. https://doi.org/10.3917/spub.134.0483
[12]
Izudi, J., Semakula, D., Sennono, R., Tamwesigire, I.K. and Bajunirwe, F. (2019) Treatment Success Rate among Adult Pulmonary Tuberculosis Patients in Sub-Saharan Africa: A Systematic Review and Meta-Analysis. BMJ Open, 9, e029400. https://doi.org/10.1136/bmjopen-2019-029400
[13]
Nomopuane Kabudri, C.M., Kandala Ngianga II, S. and Okenge Ngongo, L. (2022) Facteurs de risque de récurrence de tuberculose pulmonaire bactériologique confirmé à Kisangani (République démocratique du Congo). Santé Publique, 34, 591-600. https://doi.org/10.3917/spub.224.0591
Bouytse, K., Zagaouch, D., Bourkadi, J.E., Soualhi, M., Marc, K., Zahraoui, R., et al. (2020) Profil cliniques et radiologiques et évolutive de la tuberculose pulmonaire du sujet âgé: A propos de 61 cas. Revue des Maladies Respiratoires Actualités, 12, Article 264.
[16]
Mbatchou Ngahane, B.H., Diatta, A., Touré, N.O., et al. (2008) Profil clinique, Biologique et radiologique des nouveaux cas de tuberculose pulmonaire au Centre Hospitalier Universitaire de Fann-Dakar. Revue des Maladies Respiratoires, 25, 22-26.
[17]
Ben-Salah, N., Snene, H., Bejar, D., et al. (2018) Évaluation des connaissances attitudes et pratiques par rapport à la tuberculose selon les caractéristiques sociodémographiques en Tunisie. Revue des Maladies Respiratoires, 35, A229.
[18]
Mébiny-Essoh, T.A.A., Kiswendsida, Y.P., Séraphin, A.K., et al. (2019) Factors Associated with Pulmonary Tuberculosis Treatment Failure in Togo, 2015-2016. Journal of Public Health and Epidemiology, 11, 180-187.
[19]
Fortes Déguénonvo, L., Cissé Diallo, V., Lakhe, N., Diallo Mbaye, K., Ka, D., Diouf, A., et al. (2018) Facteurs associés au succés thérapeutique de 413 cas de tuberculose confirmée. Médecine et Maladies Infectieuses, 48, S117. https://doi.org/10.1016/j.medmal.2018.04.295
[20]
Izudi, J., Tamwesigire, I.K. and Bajunirwe, F. (2020) Treatment Success and Mortality among Adults with Tuberculosis in Rural Eastern Uganda: A Retrospective Cohort Study. BMC Public Health, 20, Article No. 501.
[21]
Mamadou, A.I., Amadou, M.H., Daouda, M.T., et al. (2020) Profil clinique, Thérapeutique et évolutif de la tuberculose au centre hospitalier régional (CHR) de Tahoua, République du Niger. Bulletin de la Societe de Pathologie Exotique, 113, Article 263.
[22]
Xu, Y., Wu, J., Liao, S. and Sun, Z. (2017) Treating Tuberculosis with High Doses of Anti-TB Drugs: Mechanisms and Outcomes. Annals of Clinical Microbiology and Antimicrobials, 16, 67.
[23]
Mouafo, J.M.F., Yakam, A.N., Simo, C., et al. (2023) Prediction of Pulmonary Tuberculosis Treatment Outcome in a Sub-Saharan African Context. Journal of Public Health in Africa, 14, Article 2694. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10658471/
[24]
Torres, N.M.C., Rodríguez, J.J.Q., et al. (2019) Factors Predictive of the Success of Tuberculosis Treatment: A Systematic Review with Meta-Analysis. PLOS ONE, 14, e0226507.
